MENLO PARK, Calif.,
Nov. 4, 2015 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for use in dermatology
and women's health, announced today that research being presented
at the Skin Disease Education Foundation's 16th Annual
Las Vegas Dermatology Seminar shows that a unique formulation of
minocycline known as BPX-01 may offer a breakthrough in acne
treatment because it can deliver the antibiotic to the area of skin
where acne develops. Study findings will be shared during the SDEF
dermatology meeting Nov. 5-7.
The novel hydrophilic (non oil-based) formulation of minocycline
may be more effective than other topical alternatives because they
either use less effective antibiotics to penetrate the top layer of
skin or rely on higher concentrations of minocycline, which could
lead to unpleasant side effects.
BPX-01 is the first and only stable hydrophilic topical gel with
fully solubilized minocycline. Minocycline, an antibacterial
and anti-inflammatory medicine, is the most commonly prescribed
acne treatment because it has a lower resistance rate than other
antibiotics. No stable form of hydrophilic topical minocycline is
currently commercially available.
"Our preliminary studies in animals indicate that minocycline
delivered by BPX-01 is efficiently absorbed into the skin, reaching
the epidermis and the pilosebaceous region where acne develops,"
said Kin F. Chan, Ph.D., executive vice president of research and
development at BioPharmX Corporation. "The results suggest that
lower doses of the antibiotic may be used to provide a treatment
that is superior to higher-dose topical formulations and oral
therapies."
Topical targeted formulations are preferable to oral dosing that
can have,side effects such as diarrhea, nausea, and dizziness that
can discourage compliance. Lipophilic (oil-based) topical
antibiotic products are occlusive and can compromise drug delivery.
To compensate for the inefficiency, some products use less
effective antibiotics while others rely on significantly higher
concentrations of antibiotics. The BioPharmX research found
that the hydrophilic BPX-01 formulation distributes evenly, is not
sticky and does not occlude or irritate the skin, an advantage in
the treatment of acne.
Dermatologists often prescribe combinations of oral minocycline
and topical products to treat the skin where acne conditions
develop, but have never had an option for a topical minocycline
solution.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 million to 50
million American at any given moment. The disease can cause
permanent scarring, low self-esteem, depression and anxiety.
About BioPharmX™ Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company, which seeks to provide products through proprietary
platform technologies for prescription, over-the-counter ("OTC"),
and supplement applications in the health and wellness markets,
including dermatology and women's health. To learn more about
BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, or the Securities Act, and Section 21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act, which are
subject to the "safe harbor" created by those section.
This press release contains forward-looking statements about the
company's expectations, plans, intentions, and strategies,
including, but not limited to, statements regarding, including with
respect to: the success of the commercialization of VI2OLET iodine,
the effectiveness of BPX01, the timing with respect to filing an
IND and clinical trials for BPX-01, the release of key data for
BPX01, the release of key data and the successful completion of
multi-site IRB studies for BPX03 and the successful completion of
the private placement with Korea Investment Partners Overseas
Expansion Platform Fund. These forward-looking statements may be
identified by words such as "plan", "expect," "anticipate,"
"believe," or similar expressions that are intended to identify
such forward-looking statements. These forward-looking
statements involve risks and uncertainties, as well as assumptions,
which, if they do not fully materialize or prove incorrect, could
cause our results to differ materially from those expressed or
implied by such forward-looking statements. The risks and
uncertainties include those described in the company's filings with
the Securities and Exchange Commission. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
BioPharmX and Violet are registered trademarks of BioPharmX,
Inc.
Logo -
http://photos.prnewswire.com/prnh/20150711/235327LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/study-shows-biopharmx-formulation-offers-more-effective-acne-treatment-by-targeted-delivery-of-minocycline-300171998.html
SOURCE BioPharmX Corporation